Document:

Exhibit
10.3

 

SYNTA PHARMACEUTICALS CORP.

AMENDED AND RESTATED*

DIRECTOR COMPENSATION POLICY

 

The Board of
Directors of Synta Pharmaceuticals Corp. (the “Company”) has approved the
following policy which establishes compensation to be paid to non-employee directors
of the Company, to provide an inducement to obtain and retain the services of
qualified persons to serve as members of the Company’s Board of Directors.  Each such director will receive as
compensation for his or her services (i) a stock option grant upon his or
her initial appointment or election to the Board of Directors of the Company, (ii) an
annual fee payable in cash and/or stock, (iii) an annual stock option
grant and (iv) additional fees for service on a committee of the Board of
Directors or as Chairman of the Board of Directors, all as further set forth
herein.

 

Applicable
Persons

 

This Policy shall
apply to each director of the Company who (a) is not an employee of the
Company or any Affiliate and (b) does not receive compensation as a consultant  to the Company or any Affiliate unless
such compensation is received solely for services provided as a member of the
Scientific Advisory Board (each, an “Outside Director”).  Affiliate shall mean a corporation which is a
direct or indirect parent or subsidiary of the Company, as determined pursuant
to Section 424 of the Internal Revenue Code of 1986, as amended.

 

Stock
Option Grant Upon Initial Appointment or Election as a Director

 

Number of Shares

 

Each new Outside
Director on the date of his or her initial appointment or election to the Board
of Directors, shall be granted a non-qualified stock option to purchase 15,000
shares of the Company’s common stock under the Company’s then applicable
stockholder-approved stock plan (the “Stock Plan”), subject to automatic
adjustment in the event of any stock split or other recapitalization affecting
the Company’s common stock.

 

Vesting Provision

 

Such option shall
vest as to 25% of such grant on the first anniversary of the date of grant of
the option and as to an additional 6.25% of such grant on the last day of each
successive three month period thereafter, provided such Outside Director
continues to serve as a member of the Board of Directors.  However, in the event of termination of
service of an Outside Director, such option shall vest to the extent of a pro
rata portion through the Outside Director’s last day of service based on the
number of days accrued in the applicable period prior to his or her termination
of service.

 

*  Amended and Restated as of
June 11, 2008. 

 

 

Exercise Price and
Term of Option

 

Each option
granted shall have an exercise price per share equal to the Fair Market Value
(as defined in the Stock Plan) of the shares of common stock of the Company on
the date of grant of the option, have a term of ten years and shall be subject
to the terms and conditions of the Stock Plan. 
Each such option grant shall be evidenced by the issuance of a
non-qualified stock option agreement.

 

Early Termination
of Option Upon Termination of Service

 

If an Outside
Director:

 

a.             ceases
to be a member of the Board of Directors for any reason other than death or
disability, any then vested and unexercised options granted to such Outside
Director may be exercised by the director within a period of three months after
the date the director ceases to be a member of the Board of Directors and in no
event later than the expiration date of the option; or

 

b.             ceases
to be a member of the Board of Directors by reason of his or her death or
disability, any then vested and unexercised options granted to such director
may be exercised by the director (or by the director’s personal representative,
or the director’s survivors) within a period of one year after the date the
director ceases to be a member of the Board of Directors and in no event later
than the expiration date of the option.

 

Annual
Fee

 

Annual Fee to Each Outside Director (the “Annual Fee”)

 

Each Outside
Director shall be compensated on an annual basis for providing services to the
Company.  Except as otherwise set forth
in this Policy, director compensation shall be paid for the period from July 1
through June 30 of each year.  Each
Outside Director shall receive compensation consisting of one of the following
combinations of cash and/or a grant of common stock, subject to certain
contractual restrictions, under the Stock Plan, at the election of each Outside
Director, as follows:

 

·      $40,000
cash,

·      $30,000
cash and such number of shares of the Company’s common stock as is equal to
$10,000 on the date of grant of the shares,

·      $20,000
cash and such number of shares of the Company’s common stock as is equal to
$20,000 on the date of grant of the shares,

·      $10,000
cash and such number of shares of the Company’s common stock as is equal to
$30,000 on the date of grant of the shares, or

·      such
number of shares of the Company’s common stock as is equal to $40,000 on the
date of the grant of the shares.

 

2

 

Additional Annual Fee to Outside Director Serving as Chairman of the
Board (the “Annual Chairman Fee”)

 

If the Chairman of
the Board of Directors is an Outside Director, he or she shall receive an
additional annual fee of $20,000 for the period from July 1 through June 30
of each year.  Such compensation shall
consist of one of the following combinations of cash and/or a grant of common
stock, subject to certain contractual restrictions, under the Stock Plan, at
the election of the Chairman of the Board of Directors, as follows:

 

·      $20,000
cash,

·      such
number of shares of the Company’s common stock as is equal to $20,000 on the
date of the grant of the shares, or

·      any
combination of cash or grant of shares that equals $20,000.

 

Calculation of
Shares

 

The number of
shares to be received by an Outside Director shall be calculated by dividing
the total dollar amount that the Outside Director has elected to be paid in
shares of common stock for his or her Annual Fee and/or his or her Annual
Chairman Fee, as applicable, by the Fair Market Value (as defined in the Stock
Plan) of the shares of common stock of the Company on the last business day
prior to the date of grant of the shares (rounded down to the nearest whole
number so that no fractional shares shall be issued).

 

Election

 

Each Outside
Director shall make an election on the form provided by the Company, indicating
the combination of his or her Annual Fee and, if applicable, his or her Annual
Chairman Fee, prior to each annual meeting of stockholders.  If the Company does not schedule an annual
meeting of stockholders to be held on or before June 30 of any year, each
Outside Director shall make his or her election(s) by June 15 of the
applicable year.

 

Cash Payments

 

Any cash portion
of the Annual Fee or Annual Chairman Fee to be paid to an Outside Director
shall be paid quarterly in arrears as of the last day of each calendar
quarter.  If an Outside Director dies,
resigns or is removed during any quarter, he or she shall be entitled to a cash
payment for his or her Annual Fee on a pro rata basis through his or her last
day of service.  If the Chairman of the
Board of Directors dies, resigns as Chairman of the Board or is removed during
any quarter, he or she shall be entitled to a cash payment for his or her
Annual Chairman Fee on a pro rata basis through his or her last day of service
as Chairman of the Board.

 

Restricted Stock
Grants

 

Shares of common
stock shall be granted at the first meeting of the Board of Directors following
each annual stockholders meeting, or if no such meeting of the Board of
Directors shall occur before June 30 of the applicable year, by unanimous
written consent dated June 30 of that year.

 

3

 

The shares issued
as all or part of the Annual Fee shall be subject to a lapsing repurchase right
such that the shares shall be subject to forfeiture to the Company if such
Outside Director does not continue to serve as a member of the Board of
Directors as of the end of the applicable quarter as follows: the repurchase
right shall lapse as to 25% of each such grant on each of September 30, December 31,
March 31 and June 30 thereafter, provided such Outside Director
continues to serve as a member of the Board of Directors as of the applicable
date.

 

The shares issued
as all or part of the Annual Chairman Fee shall be subject to a lapsing
repurchase right such that the shares shall be subject to forfeiture to the
Company if such Outside Director does not continue to serve as Chairman of the
Board of Directors as of the end of the applicable quarter as follows: the
repurchase right shall lapse as to 25% of the grant on each of September 30,
December 31, March 31 and June 30 thereafter, provided such
Outside Director continues to serve as Chairman of the Board of Directors as of
the applicable date.

 

Initial Annual Fee
and Annual Chairman Fee For Newly Appointed or Elected Directors

 

Each Outside
Director who is first appointed or elected to the Board of Directors after the
date of the adoption of this Policy shall receive his or her first year’s
Annual Fee and, if applicable, Annual Chairman Fee, prorated in accordance with
the terms of this Policy from the beginning of the next calendar quarter after
his or her initial appointment or election through the following June 30.  Each such Outside Director shall make an
election prior to the beginning of the next calendar quarter after his or her
initial appointment or election as to the combination of cash and/or
stock.  The Board of Directors shall, by
unanimous written consent dated the date of the first day of such quarter,
grant any shares to be issued to such Outside Director as part of such compensation.  Any such shares shall be subject to a pro
rata lapsing repurchase right as of the last day of each quarter remaining in
such initial period, provided, with respect to the Annual Fee, such Outside
Director continues to serve as a member of the Board of Directors, or, with
respect to the Annual Chairman Fee, such Outside Director continues to serve as
Chairman of the Board of Directors, as of the end of the applicable quarter.

 

Purchase Price and
Other Provisions Applicable to All Stock Grants

 

Shares granted
shall have a purchase price equal to the par value of the common stock on the
date of grant and shall be subject to the terms and conditions of the Stock
Plan.  The terms of such grant shall be
evidenced by a restricted stock agreement to be entered into between the
Company and the Outside Director.  In
addition, in the event of termination of service of an Outside Director, or
termination of service as Chairman of the Board of Directors, as applicable,
the Company’s lapsing repurchase right shall be deemed to have lapsed to the
extent of a pro rata portion of the shares through the Outside Director’s last
day of service as a director, or the last day of service as Chairman of the
Board of Directors, as applicable, based on the number of days accrued in the
applicable period prior to his or her termination of service.

 

4

 

Annual
Stock Option Grant

 

Number of Shares

 

At the first
meeting of the Board of Directors following each annual stockholders meeting,
or if no such meeting of the Board of Directors shall occur before June 30
of the applicable year, by unanimous written consent dated June 30 of that
year, each Outside Director shall be granted a non-qualified stock option to
purchase 5,500 shares of the Company’s common stock under the Stock Plan,
subject to automatic adjustment in the event of any stock split or other
recapitalization affecting the Company’s common stock (the “Annual Stock Option
Grants”). In addition, if on such date the Chairman of the Board of Directors
is an Outside Director, he or she shall be granted an additional non-qualified
stock option to purchase 2,500 shares of the Company’s common stock under the
Stock Plan, subject to automatic adjustment in the event of any stock split or
other recapitalization affecting the Company’s common stock (the “Annual
Chairman Stock Option Grant”).

 

Vesting Provision

 

Each Annual Stock
Option Grant shall vest as to 25% of such grant on each of September 30, December 31,
March 31 and June 30 thereafter, provided such Outside Director continues
to serve as a member of the Board of Directors. 
Each Annual Chairman Stock Option Grant shall vest as to 25% of such
grant on each of September 30, December 31, March 31 and June 30
thereafter, provided such Outside Director continues to serve as Chairman of
the Board of Directors. However, in the event of termination of service of an
Outside Director, or termination of service as Chairman of the Board of
Directors, as applicable, such option shall vest to the extent of a pro rata
portion through the Outside Director’s last day of service as a director, or
the last day of service as Chairman of the Board of Directors, as applicable,
based on the number of days accrued in the applicable period prior to his or
her termination of service.

 

Exercise Price and
Term of Option

 

Each option
granted shall have an exercise price per share equal to the Fair Market Value
(as defined in the Stock Plan) of the shares of common stock of the Company on
the date of grant of the option, have a term of ten years and shall be subject
to the terms and conditions of the Stock Plan. 
Each such option grant shall be evidenced by the issuance of a
non-qualified stock option agreement.

 

Early Termination
of Option Upon Termination of Service

 

If an Outside
Director:

 

a.             ceases
to be a member of the Board of Directors for any reason other than death or
disability, any then vested and unexercised options granted to such Outside
Director may be exercised by the director within a period of three months after
the date the director ceases to be a member of the Board of Directors and in no
event later than the expiration date of the option; or

 

b.             ceases
to be a member of the Board of Directors by reason of his or her death or
disability, any then vested and unexercised options granted to such director
may be exercised by the director (or by the director’s personal representative,
or the director’s survivors) within a period of one year after the date the
director ceases to be a member of the Board of Directors and in no event later
than the expiration 

 

5

 

date of the
option.

 

Board
Committee Compensation

 

Each Outside
Director shall also receive an annual fee of $5,000 for each Committee of the
Board of Directors on which such individual serves.  However, the Chairman of each Committee,
other than the Audit Committee, shall receive an annual fee of $10,000, and the
Chairman of the Audit Committee shall receive an annual fee of $15,000 for
services as Chairman.  Payment of such
fees shall be made quarterly in arrears on the last day of each calendar
quarter and upon death, resignation or removal, payment shall be made pro rata
through the last day of service.

 

Expenses

 

Upon presentation of
documentation of such expenses reasonably satisfactory to the Company, each
Outside Director shall be reimbursed for his or her reasonable out-of-pocket
business expenses incurred in connection with attending meetings of the Board
of Directors, Committees thereof or in connection with other Board related
business.

 

Amendments

 

The Board of
Directors shall review this Policy from time to time to assess whether any
amendments in the type and amount of compensation provided herein should be
adjusted in order to fulfill the objectives of this Policy.

 

DATED:  June 11,
2008

 

6Exhibit 10.4

 

Amendment No. 1 to
Collaborative Development, Commercialization and License Agreement

 

This amendment (the “Amendment”) dated June 27, 2008 is to the
Collaborative Development, Commercialization and License Agreement dated October 8,
2007 between Synta Pharmaceuticals Corp., a Delaware corporation with offices
at 45 Hartwell Ave., Lexington, Massachusetts 02421 (“Synta”), and SmithKline
Beecham Corporation, a Pennsylvania corporation with offices at One Franklin
Plaza, Philadelphia, Pennsylvania 19101 (“GSK”) (the “Agreement”).

 

WITNESSETH:

 

WHEREAS,
Section 6.4.1(a) of the Agreement sets forth various payments to be
made by GSK to Synta upon the achievement of certain development and regulatory
milestones;

 

WHEREAS,
the Parties desire to modify certain milestones set forth in Section 6.4.1(a) to
be achieved by Synta; and

 

WHEREAS, the Parties desire to set forth the modifications to Section 6.4.1(a) as
set forth herein, pursuant to Section 14.7 of the Agreement.

 

NOW
THEREFORE, in consideration of the foregoing and the covenants and obligations
expressed herein, the Parties agree as follows:

 

1.               Capitalized terms used herein and not
otherwise defined herein shall have the respective defined meanings set forth
in the Agreement.

 

2.               The [***] dollar
($[***]) payment payable from GSK to Synta upon achievement of the milestone
entitled “[***] for [***] in the [***] of [***] as [***]
in [***]” in Section 6.4.1(a) of
the Agreement shall be [***]
to [***] dollars ($[***]).

 

3.               A payment of [***] dollars ($[***]) shall be payable by GSK to Synta upon
achievement of a [***]
to be included in Section 6.4.1(a) for the “[***] for [***] in the [***] of [***] as [***]
in [***].”

 

4.               The [***] dollar ($[***])
payment payable from GSK to Synta upon “[***] of [***]” [***] shall be payable
upon “[***] of a [***] the [***] of [***].”

 

5.               The [***] dollar ($[***])
payment payable by GSK to Synta upon achievement of “[***] of [***] in a [***]” [***] shall be payable upon the “[***] of the [***] of [***] for the [***].”

 

6.               The [***] dollar ($[***])
payment payable from GSK to Synta upon “[***] of [***] of [***]
and [***]” [***] shall be payable upon “[***] of [***] for the [***].”
For the avoidance of doubt, “[***] of [***]
for the [***]” shall be deemed to
have been achieved 

 

 

Portions of this Exhibit
were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

 

 

upon [***]
from the [***] of the [***] from the [***] of [***] ([***], and [***]) [***] for the [***] for the [***] or [***].

 

7.               For ease of
reference, the tables in Appendix A,
attached hereto, set forth Section 6.4.1(a) as amended by the
foregoing.  GSK shall not be responsible
for any milestone payment associated with the achievement of any development or
regulatory milestones other than as set forth in Section 6.4.1(a), as
amended by this Amendment. Such payments shall be made in accordance with Section 6.4.2
of the Agreement.

 

8.               For the avoidance of doubt, nothing herein
amends or modifies the obligations of Synta to conduct the work set forth in Section 3.1.3(b) or
any other section of the Agreement.

 

9.               All other terms, conditions and provisions of
the Agreement shall remain in full force and effect except as otherwise
provided herein.  All references to the “Agreement”
therein shall mean the Agreement as amended by this Amendment.

 

10.         This Amendment may be signed in one or more counterparts, each of which
when taken together shall constitute one and the same instrument.

 

11.         This Amendment shall be governed by and construed in accordance with
the laws of the State of New York, without regard to the application of
principles of conflicts of law.

 

Portions of this Exhibit
were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

 

[Remainder of page intentionally left blank – signature page to
follow]

 

 

IN WITNESS WHEREOF, the
parties have caused this Amendment to be executed by their duly authorized
officers or representatives.

 

 

	
   

  	
   

  	
  SYNTA PHARMACEUTICALS CORP.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By: 

  	
  /s/ Safi Bahcall

  
	
   

  	
   

  	
  Name:

  	
   

  
	
   

  	
   

  	
  Title: 

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  SMITHKLINE BEECHAM CORPORATION

  
	
   

  	
   

  	
  (d/b/a GlaxoSmithKline)

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:
  

  	
  /s/
  [***]

  
	
   

  	
   

  	
  Name: 

  	
  [***]

  
	
   

  	
   

  	
  Title: 

  	
  Vice
  President & Secretary

  
						

 

Portions of this Exhibit
were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under
Rule 24b-2 of the Securities Exchange Act of 1934.

 

 

Appendix A

 

6.4.1        Milestones.

 

(a)           Development and Regulatory
Milestones.  As partial consideration for the
licenses granted to GSK by SYNTA under the terms of this Agreement, GSK  shall make the following non-refundable,
non-creditable (except as provided in Section 6.4.2(d) and Section 3.1.3(d))
payments to SYNTA:

 

	
  Indication Based 

  Milestone Events

  	
   

  	
  First Minor

  Indication

  ($ Million)

  	
   

  	
  Second

  Minor

  Indication

  ($ Million)

  	
   

  	
  First Major

  Indication

  ($ Million)

  	
   

  	
  Second Major

  Indication

  ($ Million)

  	
   

  
	
  [***] for [***] in the [***] of [***] as [***] in [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***] for [***] in the [***] of [***] as [***] in [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***] of the [***] for a [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  The earlier of (a) the date
  of determination by the JDC that the Ongoing Clinical Trial has achieved its
  primary endpoint, or (b) the date of determination by the JDC to file for
  Regulatory Approval in the U.S. Territory for STA-4783 for metastatic
  melanoma despite not meeting the primary endpoint in the Ongoing Clinical
  Trial

  	
   

  	
  25

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***] for a [***]
  in the [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***] for a [***]
  in the [***] for a [***] or any [***] if [***]
  not [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***] for a [***] in [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***] in the [***]for a [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***] in the [***] or [***] for a [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
  [***] in [***] for a [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Total

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  

 

 

	
  Other Milestone Events

  	
   

  	
  Milestone

  Payment

  ($ Millions)

  	
   

  
	
  First [***]
  of the following [***] events to occur: the [***] by the
  [***]
  that [***] the [***] for [***] the [***] the [***]
  in the [***]

  	
   

  	
  [***] for each event, for a total of [***]

  	
   

  
	
  [***] of a [***] the [***] of [***]

  	
   

  	
  [***]

  	
   

  
	
  [***] of the [***]
  of [***]
  for the [***]

  	
   

  	
  [***]

  	
   

  
	
  [***] by the [***]
  that the [***] the [***]

  	
   

  	
  [***]

  	
   

  
	
  [***] of [***] for the [***]

  	
   

  	
  [***]

  	
   

  
	
  Total

  	
   

  	
  [***]

  	
   

  

 

Portions of this Exhibit
were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}]]